About the Authors

Moaven Razavi

Affiliation Schneider Institutes for Health Policy, Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, United States of America

Donald S. Shepard

shepard@brandeis.edu

Affiliation Schneider Institutes for Health Policy, Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, United States of America

Jose A. Suaya

Affiliation GlaxoSmithKline, Philadelphia, Pennsylvania, United States of America

William B. Stason

Affiliation Schneider Institutes for Health Policy, Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, United States of America

Competing Interests

The authors have the following interests: GlaxoSmithKline Biologicals SA funded this study/research. GlaxoSmithKline Biologicals SA also undertook all costs associated with the development and publication of this manuscript. JAS is an employee of and holds stock options in the GlaxoSmithKline Group of Companies. Brandeis University received funding from GlaxoSmithKline Biologicals SA to fund part of the cost of this study. There are no patents, products in development or marketed products to declare. These statements do not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: MR DSS WBS. Performed the experiments: MR DSS WBS. Analyzed the data: MR DSS WBS. Contributed reagents/materials/analysis tools: JAS. Wrote the paper: MR DSS WBS. Contributed to model design, input parameter estimation, interpretation of the results, and review of and revisions to the study report: JAS.